NovoCure Limited reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was USD 133.78 million compared to USD 128.43 million a year ago. Net loss was USD 47.08 million compared to USD 37.3 million a year ago.

Basic loss per share from continuing operations was USD 0.45 compared to USD 0.36 a year ago.